Pradhan R, Yin H, Yu O, Azoulay L
It belongs to a novel class of drugs known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
So the idea that I came up with was to use this fatty acid isolation principle, and that's then a subclass in the class
But GLP-1 medications like Ozempic and Wegovy are proving they have decidedly more staying power
Risk of suicide, hair loss, and aspiration with GLP1-Receptor agonists and other diabetic agents: a real-world pharmacovigilance study
People with type 2 diabetes tend to lose less weight on GLP-1 medications, likely because of differences in insulin resistance and starting weight 3,4